ENTX
Entera Bio Ltd.
There isn't enough reported data to score ENTX yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ENTX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
ENTX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ENTX PE Valuation
ENTX has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ENTX Forward outlook
There aren't enough analyst estimates for ENTX to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ENTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.38 | -$0.13 |
| Q2 2026 | -$0.34 | -$0.08 |
| Q1 2026 | -$0.26 | $0.00 |
| Q4 2025 | -$0.25 | $0.00 |
| Q3 2025 | -$0.25 | +$0.01 |
| Q2 2025 | -$0.26 | $0.00 |
| Q1 2025 | -$0.26 | +$0.02 |
| Q4 2024 | -$0.25 | +$0.06 |
ENTX is still losing money, but far less than before: $0.38 per share over the past year, against $0.92 at its worst in late 2019.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over ENTX on earnings, with more consistent year-over-year improvement.
ENTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $14K | -92% |
| Q3 2022 | $8K | -94% |
| Q2 2022 | $44K | -60% |
| Q1 2022 | $68K | -57% |
| Q4 2021 | $165K | -25% |
| Q3 2021 | $140K | +180% |
| Q2 2021 | $109K | +110% |
| Q1 2021 | $157K | +274% |
ENTX's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -6102% | N/A |
| Q4 2024 | -2850% | N/A |
| Q3 2024 | -7193% | N/A |
| Q2 2024 | -3798% | N/A |
| Q4 2022 | -21914% | -19413 points |
| Q3 2022 | -35813% | -38113 points |
| Q2 2022 | -7384% | -5026 points |
| Q1 2022 | -5640% | -4150 points |
ENTX's operating margin was −6102% last quarter, up 15812 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ENTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ENTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.4M | -$4.9M |
| Q2 2026 | -$3.5M | -$1.8M |
| Q1 2026 | -$3.1M | -$1.7M |
| Q4 2025 | -$1.9M | -$390K |
| Q3 2025 | -$2.5M | -$391K |
| Q2 2025 | -$1.7M | -$325K |
| Q1 2025 | -$1.4M | +$450K |
| Q4 2024 | -$1.5M | +$1.2M |
ENTX has burned cash in almost every quarter: −$16M over the past year, against −$7M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ENTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
ENTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +188% | +94.6M shares |
| 1 year | +208% | +98M shares |
| 3 years | +403% | +116M shares |
| 5 years | +487% | +120M shares |
| Available history | +1104% | +133M shares |
ENTX has 145M diluted shares, up 208% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ENTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ENTX Net Leverage
ENTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ENTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.7 | Neutral |
| Stochastic | 58.6 | Neutral |
ENTX's weekly RSI is 67 (neutral) and its Stochastic is 59 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ENTX PE vs Healthcare Sector
ENTX has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ENTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.93 | 9.9% above |
| 20 week MA | $2.73 | 18% above |
| 50 week MA | $1.94 | 66% above |
| 100 week MA | $2.03 | 59% above |
| 200 week MA | $1.65 | 95% above |
ENTX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ENTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.01 | $1.07 | -47% |
| 2021 | $1.07 | $3.05 | +185% |
| 2022 | $3.05 | $0.55 | -82% |
| 2023 | $0.55 | $0.60 | +9.1% |
| 2024 | $0.60 | $2.15 | +258% |
| 2025 | $2.15 | $1.72 | -20% |
| 2026 YTD | $1.72 | $3.22 | +87% |
ENTX has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.